NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) News Today

$0.40

+0.01 (+2.56%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.39
▼
$0.42
50-Day Range: N/A
52-Week Range: $0.38
▼
$0.94

Volume: 245,477 shs
Average Volume: 532,624 shs
Market Capitalization: $86.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Short Interest Social Media

Get Matinas BioPharma News Delivered to You Automatically

MTNB Media Mentions By Week

MTNB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MTNB
News Sentiment
▼
0.98

0.55
▲
Average
Medical
News Sentiment

MTNB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MTNB Articles
This Week
▼
1

1
▲
MTNB Articles
Average Week

Source

Source	Headline
	Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update americanbankingnews.com - May 30 at 7:40 AM
	Matinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8M seekingalpha.com - May 12 at 12:43 PM
	Maxim Group Remains a Buy on Matinas BioPharma (MTNB) markets.businessinsider.com - May 12 at 9:18 AM
	Recap: Matinas BioPharma Hldgs Q1 Earnings msn.com - May 12 at 7:12 AM
	Why Matinas BioPharma Stock Is Sinking Today msn.com - May 11 at 1:17 PM
	Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update finanznachrichten.de - May 11 at 8:16 AM
	Q1 2023 Matinas BioPharma Holdings Inc Earnings Call finance.yahoo.com - May 11 at 8:16 AM
	Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023 finance.yahoo.com - May 11 at 8:16 AM
	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 10 at 6:43 PM
	Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update finance.yahoo.com - May 10 at 4:13 PM
	Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023 finance.yahoo.com - May 3 at 7:53 AM
	Matinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drug proactiveinvestors.com - April 28 at 1:06 PM
	CTI BioPharma Stock (NASDAQ:CTIC), Analyst Ratings, Price Targets, Predictions benzinga.com - April 23 at 9:14 AM
	Matinas jumps 25% to hit four-month high on data for anti-fungal agent msn.com - April 19 at 2:35 PM
	Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID finance.yahoo.com - April 18 at 8:51 AM
	Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX) markets.businessinsider.com - March 19 at 10:13 PM
	Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update finanznachrichten.de - March 19 at 3:37 PM
	Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript seekingalpha.com - March 18 at 3:22 PM
	Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2022 Earnings Call Transcript insidermonkey.com - March 18 at 7:15 AM
	Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Spruce Biosciences (SPRB) markets.businessinsider.com - March 17 at 3:40 PM
	Q4 2022 Matinas BioPharma Holdings Inc Earnings Call finance.yahoo.com - March 16 at 7:49 AM
	Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update finance.yahoo.com - March 15 at 6:16 PM
	Earnings Outlook For Matinas BioPharma Hldgs msn.com - March 14 at 4:59 PM
	Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023 finance.yahoo.com - March 8 at 8:38 AM
	Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID finance.yahoo.com - March 2 at 7:18 AM
	MTNB Matinas BioPharma Holdings, Inc. seekingalpha.com - February 23 at 10:22 PM
	H.C. Wainwright Keeps Their Buy Rating on Matinas BioPharma (MTNB) markets.businessinsider.com - January 31 at 7:37 AM
	Matinas BioPharma Provides Business Update and 2023 Strategic Outlook finance.yahoo.com - January 30 at 5:32 PM
	Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023 finance.yahoo.com - January 23 at 7:05 AM
	12 Hot Penny Stocks On the Rise finance.yahoo.com - January 20 at 11:35 AM
	Matinas stock rises on team up with National Resilience for drug delivery technology seekingalpha.com - January 14 at 5:59 PM
	Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids finance.yahoo.com - January 12 at 7:31 AM
	Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript seekingalpha.com - November 2 at 9:11 PM
	Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress finance.yahoo.com - November 2 at 4:10 PM
	Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022 finance.yahoo.com - October 27 at 10:42 AM
	Deadly Fungi Are Infecting More Americans finance.yahoo.com - October 24 at 7:10 AM
	Matinas BioPharma says mid-stage study for meningitis therapy met main goal seekingalpha.com - October 21 at 9:03 AM
	Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference finance.yahoo.com - October 21 at 8:23 AM
	Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% finance.yahoo.com - October 21 at 8:23 AM
	Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022 finance.yahoo.com - October 19 at 7:59 AM
	Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022 finance.yahoo.com - October 12 at 7:19 AM
	Matinas BioPharma Announces Chairman Succession Plan finance.yahoo.com - September 21 at 7:05 AM
	Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com - September 7 at 9:27 AM
	Matinas BioPharma Holdings Inc (6LJ.MU) finance.yahoo.com - September 4 at 7:12 PM
	After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB) finance.yahoo.com - August 30 at 1:06 PM
	Matinas BioPharma: Q2 Earnings Insights msn.com - August 11 at 4:12 PM
	Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress finance.yahoo.com - August 11 at 4:12 PM
	Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 11 at 4:12 PM
	Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022 finance.yahoo.com - July 28 at 5:19 PM
	Matinas: MAT2203 Gets EMA Positive Opinion On Orphan Drug Designation To Treat Cryptococcosis markets.businessinsider.com - July 25 at 7:58 AM

Get Matinas BioPharma News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NYSEAMERICAN:MTNB) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Matinas BioPharma (MTNB) News Today

MTNB Media Mentions By Week

MTNB Media Sentiment

MTNB News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info